Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Skinvisible (SKVI) Amortization of Deferred Charges (2016 - 2024)

Historic Amortization of Deferred Charges for Skinvisible (SKVI) over the last 14 years, with Q4 2024 value amounting to $12814.0.

  • Skinvisible's Amortization of Deferred Charges rose 0.78% to $12814.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $50973.0, marking a year-over-year decrease of 9601.43%. This contributed to the annual value of $50973.0 for FY2024, which is 9601.43% down from last year.
  • Latest data reveals that Skinvisible reported Amortization of Deferred Charges of $12814.0 as of Q4 2024, which was up 0.78% from $12813.0 recorded in Q3 2024.
  • Skinvisible's Amortization of Deferred Charges' 5-year high stood at $1.2 million during Q1 2023, with a 5-year trough of $12673.0 in Q1 2024.
  • Its 5-year average for Amortization of Deferred Charges is $165021.0, with a median of $165067.0 in 2020.
  • As far as peak fluctuations go, Skinvisible's Amortization of Deferred Charges soared by 65189.31% in 2023, and later plummeted by 9897.85% in 2024.
  • Over the past 5 years, Skinvisible's Amortization of Deferred Charges (Quarter) stood at $168624.0 in 2020, then decreased by 10.88% to $150276.0 in 2021, then rose by 9.98% to $165276.0 in 2022, then plummeted by 92.25% to $12813.0 in 2023, then rose by 0.01% to $12814.0 in 2024.
  • Its last three reported values are $12814.0 in Q4 2024, $12813.0 for Q3 2024, and $12673.0 during Q2 2024.